Lonza would add drug delivery tech through Catalent merger, analyst

By Dan Stanton contact

- Last updated on GMT

Related tags: Chemical industry, Dsm

Image: iStock
Image: iStock
Lonza acquiring Catalent would make “strategic sense,” according to an analyst as rumours circulate about a CMO megamerger.

Swiss contract manufacturing organisation (CMO) Lonza has put in a bid to buy fellow manufacturer and delivery tech firm Catalent, Reuters wrote yesterday​ citing people familiar with the matter.

A spokesman from Lonza told this publication it does “not comment on market speculations,”​ while a spokesman from Catalent sent us a similar statement

William Blair analyst John Kreger said: “This sort of combination would make strategic sense.”​  

He wrote in a note that “Catalent is a market leader in a number of advanced drug delivery technologies—particularly for small molecules,”​ and has expanded its offerings over the past few years through its own growth and M&A strategy.

The firm, for example, acquired particle size engineering tech firm Micron Technologies​ and bioconjugation experts Redwood Bioscience​ in 2014, and has been growing its oral dosage network through various deals​ and expansions​.

Meanwhile, Kreger noted, “Lonza, in contrast, is a leader contract biologic manufacturing,” ​and while Catalent has a single-use biologics facility in Madison, Wisconsin – acquired from GE Healthcare in 2011​ – “the company has relatively little exposure to biologics, and this has been noted as a key M&A target.”

If a deal was to be made, it would be the latest example of consolidation in a sector currently deemed ripe for consolidation​, and likely to be larger than the $2.65bn merger​ of rival Patheon with Royal DSM’s pharmaceutical products business in 2014.

Kreger believes $35 would be a reasonable per share take-out price, which would value the company at close to $1.5bn.

According to Reuters, the firms have failed to agree on a price, and Lonza may decide to pursue other targets.

Related news

Show more

Related products

show more

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us


View more